Cerus (CERS) is up over 60% since April 1
Today's Financial News - Posted April 21, 2009
Biotech Cerus has seen its share price scale the resistance wall to reach a 61% increase this month. What’s the savvy investor to do at this point?
by Laura Cadden, TodaysFinancialNews.com
Baltimore (TFN): If you acted on our Jan. 12 recommendation to buy Cerus Corporation (NASDAQ:CERS) in our report Four Biotechs Set to Soar, you are sitting on gains of over 20%.
The lucky folks who came in later when the stock was truly battered, are sitting on much higher gains.
The company’s technology is primarily focused on its INTERCEPT System which destroys pathogens of all types in donated blood components.
With the increased use of plasma and platelets, as well as the limited availability of donated blood, it is more essential than ever to make those components safe.
I think Cerus has a great future, but I don’t want to lose these gains…
I recommend you put in place a 20% stop-loss. If you got in at our initial price of $0.87, that would mean you sell your shares if the price drops back to $1.04.
Next Article: Airline industry pulls out of a nosedive
Be the first to leave a reply.
Your comments are welcome
Follow TFN via RSS or Twitter |
 |
 |
 |
Advertisement
Latest Headlines
- The Big Picture for Sinobiopharma, Inc. (SNBP)
- Beazer Homes USA, Inc. (BZH) and Hovnanian Enterprises, Inc. (HOV) up despite horrid housing news
- The FDA catalyst: 2010 moves in MannKind (MNKD), Roche Holding (RHHBY), Acorda Therapeutics (ACOR) show it still works!
- Steepest drop since Feb. 2009: Here we go again!
- Is the silver run over? Coeur d’Alene Mines (CDE), Silver Wheaton (SLW), Alto Group (ALTO), Hecla Mining (HL), Endeavour Silver (EXK) close down